CN103316352A - 氧化石墨烯纳米药物载体、抗肿瘤药物及其制备方法 - Google Patents
氧化石墨烯纳米药物载体、抗肿瘤药物及其制备方法 Download PDFInfo
- Publication number
- CN103316352A CN103316352A CN2013102571879A CN201310257187A CN103316352A CN 103316352 A CN103316352 A CN 103316352A CN 2013102571879 A CN2013102571879 A CN 2013102571879A CN 201310257187 A CN201310257187 A CN 201310257187A CN 103316352 A CN103316352 A CN 103316352A
- Authority
- CN
- China
- Prior art keywords
- pyrenyl
- polyethylene glycol
- graphene oxide
- graphene
- pharmaceutical carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 129
- 229910021389 graphene Inorganic materials 0.000 title claims abstract description 129
- 239000003937 drug carrier Substances 0.000 title claims abstract description 63
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 43
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 69
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 62
- IVCXPKNSONVWNU-UHFFFAOYSA-N 1-(pyren-1-yldisulfanyl)pyrene Chemical group C1=C2C(SSC=3C4=CC=C5C=CC=C6C=CC(C4=C65)=CC=3)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 IVCXPKNSONVWNU-UHFFFAOYSA-N 0.000 claims abstract description 51
- 230000000694 effects Effects 0.000 claims abstract description 42
- 239000002105 nanoparticle Substances 0.000 claims abstract description 30
- 125000001725 pyrenyl group Chemical group 0.000 claims abstract description 12
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 claims description 96
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 72
- 239000003814 drug Substances 0.000 claims description 49
- 230000002209 hydrophobic effect Effects 0.000 claims description 36
- 230000000259 anti-tumor effect Effects 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 31
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims description 21
- 229940099500 cystamine Drugs 0.000 claims description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- -1 1-ethyl-(3-dimethylaminopropyl) Chemical group 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical group C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 13
- 229930195573 Amycin Natural products 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 230000003993 interaction Effects 0.000 claims description 10
- 229920001427 mPEG Polymers 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- QXYRRCOJHNZVDJ-UHFFFAOYSA-N 4-pyren-1-ylbutanoic acid Chemical compound C1=C2C(CCCC(=O)O)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 QXYRRCOJHNZVDJ-UHFFFAOYSA-N 0.000 claims description 8
- 229930012538 Paclitaxel Natural products 0.000 claims description 7
- 229960001592 paclitaxel Drugs 0.000 claims description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 4
- 230000011987 methylation Effects 0.000 claims description 4
- 238000007069 methylation reaction Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000004048 modification Effects 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 13
- 229960003180 glutathione Drugs 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 230000008901 benefit Effects 0.000 description 8
- 235000003969 glutathione Nutrition 0.000 description 7
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000002228 disulfide group Chemical group 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 241000446313 Lamella Species 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960003857 proglumide Drugs 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310257187.9A CN103316352B (zh) | 2013-06-25 | 2013-06-25 | 氧化石墨烯纳米药物载体、抗肿瘤药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310257187.9A CN103316352B (zh) | 2013-06-25 | 2013-06-25 | 氧化石墨烯纳米药物载体、抗肿瘤药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103316352A true CN103316352A (zh) | 2013-09-25 |
CN103316352B CN103316352B (zh) | 2018-09-07 |
Family
ID=49185583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310257187.9A Active CN103316352B (zh) | 2013-06-25 | 2013-06-25 | 氧化石墨烯纳米药物载体、抗肿瘤药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103316352B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103784407A (zh) * | 2014-02-26 | 2014-05-14 | 哈尔滨医科大学 | 一种叶酸介导的peg-氧化石墨烯负载阿霉素纳米粒及其制备方法 |
CN104826128A (zh) * | 2015-04-30 | 2015-08-12 | 中国药科大学 | 生物体病灶部位触发释药的多糖修饰的氧化石墨烯载体及其药学组合物的制备和应用 |
CN105999291A (zh) * | 2016-04-23 | 2016-10-12 | 上海大学 | 提高石墨烯量子点载带药物阿霉素量的方法 |
CN106421804A (zh) * | 2016-10-21 | 2017-02-22 | 曲阜师范大学 | 一种氟化石墨烯纳米药物载体及其制备方法和应用 |
CN106692975A (zh) * | 2016-12-01 | 2017-05-24 | 浙江大学常州工业技术研究院 | 一种具有靶向作用的基于氧化石墨烯的纳米药物载体及其制备方法 |
CN110973156A (zh) * | 2019-11-28 | 2020-04-10 | 自然资源部第三海洋研究所 | 一种氧化石墨烯/迷迭香酸复合材料及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102274521A (zh) * | 2011-08-25 | 2011-12-14 | 天津医科大学 | 基于氧化石墨烯的靶向性基因载体材料及制备和应用 |
CN102320599A (zh) * | 2011-08-02 | 2012-01-18 | 同济大学 | 一种纳米氧化石墨烯表面聚合物功能化的方法 |
CN102502607A (zh) * | 2011-11-10 | 2012-06-20 | 郑州大学 | 一种基于超临界二氧化碳和芘基聚合物制备石墨烯溶液的方法 |
CN102585425A (zh) * | 2011-12-21 | 2012-07-18 | 青岛大学 | 一种温敏可控的石墨烯-高分子复合材料的制备方法 |
-
2013
- 2013-06-25 CN CN201310257187.9A patent/CN103316352B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102320599A (zh) * | 2011-08-02 | 2012-01-18 | 同济大学 | 一种纳米氧化石墨烯表面聚合物功能化的方法 |
CN102274521A (zh) * | 2011-08-25 | 2011-12-14 | 天津医科大学 | 基于氧化石墨烯的靶向性基因载体材料及制备和应用 |
CN102502607A (zh) * | 2011-11-10 | 2012-06-20 | 郑州大学 | 一种基于超临界二氧化碳和芘基聚合物制备石墨烯溶液的方法 |
CN102585425A (zh) * | 2011-12-21 | 2012-07-18 | 青岛大学 | 一种温敏可控的石墨烯-高分子复合材料的制备方法 |
Non-Patent Citations (1)
Title |
---|
HUIYUN WEN, ET AL.: "Engineered redox-responsive PEG detachment mechanism in PEGlated nano-graphene oxide for intracellular drug delivery", 《SMALL》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103784407A (zh) * | 2014-02-26 | 2014-05-14 | 哈尔滨医科大学 | 一种叶酸介导的peg-氧化石墨烯负载阿霉素纳米粒及其制备方法 |
CN103784407B (zh) * | 2014-02-26 | 2016-01-20 | 哈尔滨医科大学 | 一种叶酸介导的peg-氧化石墨烯负载阿霉素纳米粒及其制备方法 |
CN104826128A (zh) * | 2015-04-30 | 2015-08-12 | 中国药科大学 | 生物体病灶部位触发释药的多糖修饰的氧化石墨烯载体及其药学组合物的制备和应用 |
CN104826128B (zh) * | 2015-04-30 | 2018-04-24 | 中国药科大学 | 生物体病灶部位触发释药的多糖修饰的氧化石墨烯载体及其药学组合物的制备和应用 |
CN105999291A (zh) * | 2016-04-23 | 2016-10-12 | 上海大学 | 提高石墨烯量子点载带药物阿霉素量的方法 |
CN106421804A (zh) * | 2016-10-21 | 2017-02-22 | 曲阜师范大学 | 一种氟化石墨烯纳米药物载体及其制备方法和应用 |
CN106421804B (zh) * | 2016-10-21 | 2019-09-03 | 曲阜师范大学 | 一种氟化石墨烯纳米药物载体及其制备方法和应用 |
CN106692975A (zh) * | 2016-12-01 | 2017-05-24 | 浙江大学常州工业技术研究院 | 一种具有靶向作用的基于氧化石墨烯的纳米药物载体及其制备方法 |
CN110973156A (zh) * | 2019-11-28 | 2020-04-10 | 自然资源部第三海洋研究所 | 一种氧化石墨烯/迷迭香酸复合材料及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103316352B (zh) | 2018-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103316352A (zh) | 氧化石墨烯纳米药物载体、抗肿瘤药物及其制备方法 | |
Huang et al. | Phthalocyanine-based coordination polymer nanoparticles for enhanced photodynamic therapy | |
CN101254309A (zh) | 叶酸受体介导靶向乙酰普鲁兰多糖纳米粒及制备方法 | |
CN103251561B (zh) | 一种双敏感可崩解式纳米囊泡药物载体制剂及其制备方法 | |
CN101708162A (zh) | 纳米颗粒及其制备方法 | |
CN104162169B (zh) | 一种药物组合物的制备方法 | |
CN109010846A (zh) | 聚乙二醇-壳聚糖-姜黄素聚合物、及其载药纳米粒子和制备方法 | |
CN104840977A (zh) | 一种磁性荧光复合纳米药物载体的制备方法 | |
CN111870579B (zh) | 一种肿瘤靶向纳米胶束、制备方法及作为药物载体的应用 | |
CN103193944A (zh) | 一种具有肿瘤靶向性及可见光降解性的两亲性聚合物、药物载体及其制备方法 | |
CN103446588B (zh) | 靶向型诊疗联用药物及其制备方法和应用 | |
CN109846857B (zh) | 一种活性天然超分子光敏剂的制备方法及其应用 | |
CN108969480A (zh) | 一种近红外光响应性光动药物控释***及其制备方法 | |
CN103239718B (zh) | 负载阿霉素的聚己内酯-嵌段-聚乙二醇纳米微球的制备方法 | |
CN105327362B (zh) | 一种两亲性聚合物刷修饰的石墨烯靶向性药物载体的制备方法 | |
CN108395543B (zh) | 一种改性聚轮烷、基于聚轮烷的载药胶束及其制备方法与应用 | |
Wang et al. | Tunable Zeolitic Imidazolate Framework‐8 Nanoparticles for Biomedical Applications | |
Yadav et al. | Chondroitin sulphate decorated nanoparticulate carriers of 5-fluorouracil: development and in vitro characterization | |
Wu et al. | Self-assembly-induced near-infrared fluorescent nanoprobes for effective tumor molecular imaging | |
CN104434792A (zh) | 聚合物胶束及其制备方法和抗肿瘤药物组合物、制剂及其制备方法 | |
CN105055322A (zh) | 甲氨喋呤磷脂复合物、其纳米粒子及其靶向缓释制剂三者的制备方法 | |
CN109908358B (zh) | 一种熊果酸聚合物载药纳米粒及其制备方法和应用 | |
CN109265658B (zh) | 一种基于阿魏酸聚合物的载药纳米粒及其制备方法和应用 | |
CN110917349A (zh) | 一种碗状isp复合功能性纳米粒子及其制备方法和应用 | |
JP5201763B2 (ja) | 異なる平均粒径サイズの粒子からなる混合微粒子カプセルの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240116 Address after: Room a-207, office building, Shenzhen Institute of advanced technology, Chinese Academy of Sciences, 1068 Xueyuan Avenue, Shenzhen University Town, Nanshan District, Shenzhen, Guangdong 518055 Patentee after: Shenzhen advanced science and technology Cci Capital Ltd. Address before: 1068 No. 518055 Guangdong city in Shenzhen Province, Nanshan District City Xili University School Avenue Patentee before: SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY CHINESE ACADEMY OF SCIENCES |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240423 Address after: Floor 8, No. 229, Gongchang Road, Zhenmei Community, Xinhu Street, Guangming District, Shenzhen, Guangdong 518000 Patentee after: Shenzhen Biological Manufacturing Industry Innovation Center Co.,Ltd. Country or region after: China Address before: Room a-207, office building, Shenzhen Institute of advanced technology, Chinese Academy of Sciences, 1068 Xueyuan Avenue, Shenzhen University Town, Nanshan District, Shenzhen, Guangdong 518055 Patentee before: Shenzhen advanced science and technology Cci Capital Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |